Pulmonomy is a bio-pharmaceutical company, ushering in a new era of Pulmonary Therapeutics. Our inhalation therapeutics target a range of life threatening infections. We develop novel treatments for patients who are immunocompromised . Our approach is a result of innovative molecular design in concert with optimal particle engineering for effective delivery. We have a pipeline of dry powder inhalation therapeutics in development.